Risk-reducing medications for primary breast cancer: a network meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risk-reducing medications for primary breast cancer: a network meta-analysis

Published:2019-04-29 Issue: Volume: Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Mocellin Simone¹²,Goodwin Annabel³⁴⁵,Pasquali Sandro⁶

Affiliation:

1. Istituto Oncologico Veneto, IOV-IRCCS; Surgical Oncology Unit; Via Gattamelata 64 Padova Veneto Italy 35128

2. University of Padova; Department of Surgery Oncology and Gastroenterology; Padova Veneto Italy 35128

3. The University of Sydney, Concord Repatriation General Hospital; Concord Clinical School; Concord NSW Australia 2137

4. Concord Repatriation General Hospital; Medical Oncology Department; Concord Australia

5. Sydney Local Health District and South Western Sydney Local Health District; Cancer Genetics Department; Sydney Australia

6. Fondazione IRCCS Istituto Nazionale dei Tumori; Sarcoma Service; Via G. Venezian 1 Milano Italy 20133

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012191.pub2/epdf/full

Reference136 articles.

1. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial;Cuzick;Lancet,2014

2. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial;Cuzick;Lancet Oncology,2015

3. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study;Fisher;Journal of the National Cancer Institute,2005

4. Exemestane for breast-cancer prevention in postmenopausal women;Goss;New England Journal of Medicine,2011

5. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial;Powles;Journal of the National Cancer Institute,2007

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape;Current Oncology Reports;2024-06-01

2. Body composition changes during breast cancer preventive treatment with anastrozole: Findings from the IBIS-II trial;Preventive Medicine Reports;2024-02

3. How do network meta-analyses address intransitivity when assessing certainty of evidence: a systematic survey;BMJ Open;2023-11

4. Chemoprevention and Lifestyle Modifications for Risk Reduction in Sporadic and Hereditary Breast Cancer;Healthcare;2023-08-21

5. Management of breast cancer patients with BRCA gene mutations in Jordan: perspectives and challenges;Hospital Practice;2023-08-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3